Across 164 Phase 3 haematology trials authorized in 2024–2026, the European site footprint is highly concentrated: France, Italy, Germany, and Spain account for 2,990 of 4,294 country-level site allocations, or 69.6%. Assistance Publique Hopitaux De Paris is the leading named site organization with 51 trial participations, while small molecules appear in 102 of 164 trials and CRO support is present in 96 of 164 trials.
Assistance Publique Hopitaux De Paris leads the ranking with 51 trial participations, equal to 31.1% of the 164-trial cohort. The top 10 named organizations are dominated by France, Spain, and Italy, showing that Phase 3 haematology trial access clusters around large academic hospital systems.
The top site list is not evenly distributed across Europe: it is anchored by multi-site French hospital systems and major Spanish and Italian academic centers. For sponsors planning haematology Phase 3 feasibility, these organizations represent the highest-density starting points for site identification.
France contributes 1,029 of 4,294 country-level site allocations, or 24.0%. Italy, Germany, and Spain add another 1,961 allocations, meaning the top four countries together account for 2,990 of 4,294 allocations, or 69.6%.
The country footprint is operationally concentrated. Sponsors can reach most Phase 3 haematology site capacity by prioritizing France, Italy, Germany, and Spain before expanding into secondary contributors such as Poland, Belgium, the Netherlands, and Greece.
France has the largest country-level planned participant allocation, with 11,010 of 35,192 patients, or 31.3%. Germany and Italy follow with 6,247 and 6,077 patients respectively; the top three countries together represent 23,334 of 35,192 patients, or 66.3%.
| Country | Patients | Share |
|---|---|---|
| France | 11,010 | 31.3% |
| Germany | 6,247 | 17.8% |
| Italy | 6,077 | 17.3% |
| Spain | 2,893 | 8.2% |
| Poland | 1,177 | 3.3% |
| Sweden | 1,047 | 3.0% |
| Netherlands | 937 | 2.7% |
| Czechia | 908 | 2.6% |
| Austria | 757 | 2.2% |
| Greece | 652 | 1.9% |
Patient allocations are even more concentrated than site allocations. France, Germany, and Italy form the core enrolment geography, while Spain is a strong secondary anchor with 2,893 planned patient allocations.
Hemoglobinopathy, bleeding, and anemia trials are the largest disease group by trial count, with 48 of 164 trials, or 29.3%. Plasma cell disorders and amyloidosis drive the largest site footprint, with 985 of 4,294 site allocations, or 22.9%, and 7,528 of 34,613 trial-level planned participants, or 21.8%.
| Disease cluster | Trials | Sites | Site share |
|---|---|---|---|
| Plasma cell disorders / amyloidosis | 21 | 985 | 22.9% |
| Hemoglobinopathy / bleeding / anemia | 48 | 694 | 16.2% |
| Lymphoma / B-cell malignancies | 23 | 681 | 15.9% |
| Complement / immune hematology | 18 | 462 | 10.8% |
| Acute myeloid leukemia (AML) | 16 | 405 | 9.4% |
| MDS / myeloproliferative neoplasms | 12 | 402 | 9.4% |
| Acute lymphoblastic leukemia (ALL) | 8 | 296 | 6.9% |
Non-malignant haematology contributes many trials, but malignant haematology drives large site and patient footprints. Plasma cell disorders, lymphoma, AML, ALL, and MDS/myeloproliferative neoplasms together account for 2,769 of 4,294 site allocations, or 64.5%.
Small molecules appear in 102 of 164 trials, or 62.2%, making them the dominant Phase 3 modality. Monoclonal antibodies appear in 58 of 164 trials, or 35.4%, while peptide/protein/enzyme therapies appear in 35 of 164 trials, or 21.3%; modality counts are trial-level presences, so combination trials may contribute to more than one modality.
Phase 3 haematology is still driven by conventional and antibody-based modalities, but advanced modalities matter operationally: bispecific antibodies, cell therapy, gene therapy, and ADCs together appear in 37 trial-level modality records, creating specialist site-selection needs beyond standard pharmacy and infusion capacity.
CRO support is present in 96 of 164 trials, or 58.5%. CRO use increases sharply once the footprint exceeds five sites: 13 of 39 trials with 0–5 sites use CROs, compared with 39 of 56 trials with 31 or more sites.
CRO use becomes the norm once Phase 3 haematology trials move beyond very small footprints. The inflection point is visible above five sites, where roughly two-thirds of trials use CRO support.
Among 96 CRO-supported trials, Icon Clinical Research Limited appears in 27 trials, or 28.1%, followed by IQVIA Limited in 20 trials, or 20.8%, and Parexel International (IRL) Limited in 13 trials, or 13.5%.
| CRO | Trials | Share of CRO-supported trials |
|---|---|---|
| Icon Clinical Research Limited | 27 | 28.1% |
| IQVIA Limited | 20 | 20.8% |
| Parexel International (IRL) Limited | 13 | 13.5% |
| Medidata Solutions Inc. | 11 | 11.5% |
| Syneos Health Inc. | 11 | 11.5% |
| PPD Development LP | 10 | 10.4% |
The CRO landscape is concentrated but not monopolized. Icon and IQVIA are the two most frequent vendors, but the presence of Parexel, Medidata, Syneos, PPD, and specialist service providers shows that Phase 3 haematology outsourcing is distributed across both full-service CROs and functional vendors.